SPRAVATO label update approved; J&J vision, hip, and lumateperone trials advanceSep 18Weekly roundup, 6 itemsesketamineJohnson & Johnson
Janssen registers Phase 3 esketamine nasal spray trial for treatment-resistant depressionJul 21Weekly roundup, 2 itemsesketamineJohnson & Johnson
J&J raises 2026 sales and EPS guidance after strong Q2 resultsJul 15Quarterly updateJohnson & Johnson
Sign inSign in